- TLDR Biotech
- Archive
- Page 10
The Latest Biotech & Pharma Updates
Biotech & Pharma Updates | November 25 - 26, 2024
Roche paying a pretty penny for Poseida's allogeneic cell therapy ambitions, Amgen's MariTide weight loss Ph2 data isn't enough for investors, Cradle Bio $73M Series B for AI-driven protein design, Roche’s anti-TIGIT mAb misses in lung cancer Ph3 + 26 more stories
Biotech & Pharma Updates | November 24 - 25, 2024
Cassava's much-controversial Alzheimer's hopeful flunks in Ph3, Alnylam whips out the priority review voucher for cardiomyopathy asset, Adcendo's ADC hopes get $135M injection, AstraZeneca touts Truqap prostrate cancer subtype Ph3 win + 27 more stories
Biotech & Pharma Updates | November 21 - 24, 2024
BridgeBio's Attruby lands FDA approval, Roche's Vabysmo touts potentially lucrative (in Asia) Ph3b/4 data in polypoidal choroidal vasculopathy, Nabla Bio's coming for the AI-designed protein crown, ALS hopeful Seelos Therapeutics files for bankruptcy + 21 more stories
Biotech & Pharma Updates | November 20 - 21, 2024
Novartis buys gene therapy's Kate Therapeutics for up to $1.1B, Enveda snags $130M Series C on AI-analyzed plant-derived molecules, Pharma ads might go bye-bye if RFK Jr. has his way, CBER's Peter Marks sees vaccine debates as not "a bad thing", Pyxis Oncology’s PYX-201 Ph1 data doesn't inspire investor confidence + 25 more stories
Biotech & Pharma Updates | November 19 - 20, 2024
Pfizer signs drug discovery partnerships with two Flagship portfolio companies, Samsung Biologics scores a bunch of European manufacturing deal, Novartis and Vyriad partner on in-vivo CAR-T generation, Sage Therapeutics' potentially fatal Ph2 blow, RFK Jr. wants to "blow...up" the FDA + 29 more stories
Biotech & Pharma Updates | November 18 - 19, 2024
Dr. Oz to lead Medicare & Medicaid, “fail fast” biotech venture foundry Jupiter Bioventures launches with $70M, BeiGene (soon to BeOne Medicines) settles Brukinsa generic spat with MSN Pharmaceuticals, AstraZeneca’s Andexxa FDA adcom chances not looking good after “major safety findings” + 31 more stories
Biotech & Pharma Updates | November 17 - 18, 2024
Intellia's rare heart disorder CRISPR therapy looks solid in Ph1, AstraZeneca exercises option for Quell Therapeutics cell therapy, Novartis & Ratio Therapeutics' $745M radiotherapy development partnership, Neurogene stock drops even further as one Rett syndrome gene therapy recipient now in “critical condition” + 29 more stories
Biotech & Pharma Updates | November 12 - 13, 2024
BioNTech buys bispecific partner Biotheus for $800M, PTC Therapeutics rare disease gene therapy Kebilidi land FDA approval, Adaptimmune touts positive Ph2 lete-cel data, Metsera $215M Series B to fuel obesity ambitions, UK’s NICE agrees to reassess Sanofi’s Sarclisa, Sanofi & Healx partner on finding indications to match a discontinued late stage asset, ICU Medical & Otsuka Pharmaceutical Factory partner on bolstering North American IV solution network, Syros Pharmaceuticals myelodysplastic syndrome drug combo misses Ph3 endpoint, Marinus Pharmaceuticals cuts 45% of staff, a hidden spreadsheet tab cost Amgen $12B in market cap, FDA continues struggling with retaining drug manufacturing site inspectors
Biotech & Pharma Updates | November 11 - 12, 2024
Trace Neuroscience launches with $101M and ALS therapy goals, Apollo Therapeutics buys ex-China rights to Sunshine Lake Pharma diabetes clinical asset, Alentis Therapeutics $181.4M Series D to accelerate ADC pipeline, AstraZeneca plans $3.5B & 1000+ jobs investment in the US, Roche & Flare Therapeutics collaborate on cancer drug discovery, Intercept Pharmaceutical’s full Ocaliva approval rejected by FDA, Neurogene stock collapses after Rett syndrome gene therapy serious adverse event, Bayer’s CEO calls Q3 earnings “not pretty”, Pfizer considers hospital drugs business divestiture as activist investor pressure continues, AstraZeneca’s CEO says they didn’t “lose oversight” regarding Chinese executive criminal investigations